On November 3, 2025, TuHURA Biosciences, Inc. entered into an agreement to potentially sell up to $50 million worth of its common stock through H.C. Wainwright & Co., with the intention of using the funds for working capital. The sales may occur at market prices, but the company is not obligated to sell any shares under this agreement.